EUVIMEDAtrasti EUVIMED
CrossrefInformacijos kortelė

Extracellular galectin-3 preferentially through CD44 and PD-1 binds activated T cells and marks memory-phenotype T cell subsets

Amal Abouda, Emmanuel T. Alimo, Ako Azimi, AmirAli Bigleri, Amirhossein Rahmati, Shima Shahbaz, Shokrollah Elahi

Frontiers in Immunology · 2026-11-04 · 17

DOI: 10.3389/fimmu.2026.1940192 ↗
SantraukaBibliografiniai duomenys

Santrauka

Background Galectin-3 (Gal-3) is a multifunctional β-galactoside-binding lectin implicated in immune regulation, yet its association with T cell phenotypes under physiological and inflammatory conditions remains incompletely defined. Methods We investigated Gal-3 expression and binding on murine and human T cells across developmental stages, tissues, sex, genetic background, circadian time, and inflammatory disease settings. Results In mice, Gal-3-associated CD4 + and CD8 + T cells were dynamically regulated by age, anatomical location, strain, sex, and circadian rhythm. Gal-3 + T cells displayed increased activation markers, enhanced TCR-associated signaling molecules, elevated cytolytic mediators, increased proliferation, and greater apoptosis. Gal-3 + T cells were enriched within central and effector memory compartments and expressed higher levels of co-inhibitory receptors, including PD-1, with ImageStream analysis confirming Gal-3 co-expressed with PD-1. Recombinant Gal-3 preferentially bound activated, but not resting T cells, and associated with CD44 and CD3, suggesting activation-dependent acquisition of extracellular Gal-3. Re-analysis of human thymocyte and Long COVID single-cell RNA-seq datasets further supported an association between LGALS3 expression and activated/exhausted T cell states. Finally, intracellular staining indicated that T cells are unlikely to be a major source of Gal-3. Conclusion Our findings identify Gal-3 as a context-dependent marker and potential regulator of activated, antigen-experienced T cells, which promotes T cell apoptosis.

Jūsų darbui tinkamos žinios.

Nuo nemokamos pradžios ir asmeninės literatūros paieškos iki viso Research Suite.

Peržiūrėti tarifus →

Ar įtraukti visi leidėjų pilnieji tekstai?

Ne. Bibliografiniai įrašai, santraukos ir pilnieji tekstai yra skirtingas turinys. Ar pilnasis tekstas prieinamas, priklauso nuo šaltinio, Open Access ir jūsų turimų licencijų. EUVIMED planas nepakeičia papildomų leidėjų teisių.

Peržiūrėti tarifus →